炎症诱导去分化介导免疫治疗耐药
本文报道一例转移性黑色素瘤患者在接受靶向MART1抗原的过继性T细胞治疗(ACT)后,肿瘤先消退后复发,复发肿瘤丢失黑色素细胞抗原(MART1、gp100)并表达炎症诱导的神经嵴标志物NGFR,提示炎症诱导的去分化是免疫治疗获得性耐药的机制。
要点
- ACT后复发病灶丢失MART1/gp100并表达NGFR。
- 体外实验显示MART1 TCR-T或TNFα可诱导该耐药表型。
- 撤除炎症刺激后耐药表型可逆。
核心结论
- 癌症免疫治疗的获得性耐药可能由炎症诱导的肿瘤去分化介导。
研究设计与样本
- 病例报告:一例接受靶向MART1抗原的过继性T细胞治疗(ACT)的转移性黑色素瘤患者。
- 体外实验使用人黑色素瘤细胞系。
主要发现
- 患者经ACT后肿瘤 initially 消退,复发时肿瘤缺乏黑色素细胞抗原(MART1、gp100)并表达炎症诱导的神经嵴标志物NGFR。
- 体外用人黑色素瘤细胞系证明,用表达MART1 TCR的T细胞或TNFα处理可诱导该耐药表型。
- 撤除炎症刺激后该表型可逆。
临床怎么用
- 未来黑色素瘤ACT方案可能受益于同时靶向多个肿瘤抗原、调节炎症反应及抑制炎症性去分化诱导信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new mechanisms of tumor-acquired resistance. We report here a patient whose metastatic melanoma underwent dedifferentiation as a resistance mechanism to adoptive T-cell transfer therapy (ACT) to the MART1 antigen, a phenomenon that had been observed only in mouse studies to date. After an initial period of tumor regression, the patient presented in relapse with tumors lacking melanocytic antigens (MART1, gp100) and expressing an inflammation-induced neural crest marker (NGFR). We demonstrate using human melanoma cell lines that this resistance phenotype can be induced in vitro by treatment with MART1 T cell receptor-expressing T cells or with TNFα, and that the phenotype is reversible with withdrawal of inflammatory stimuli. This supports the hypothesis that acquired resistance to cancer immunotherapy can be mediated by inflammation-induced cancer dedifferentiation.Significance: We report a patient whose metastatic melanoma underwent inflammation-induced dedifferentiation as a resistance mechanism to ACT to the MART1 antigen. Our results suggest that future melanoma ACT protocols may benefit from the simultaneous targeting of multiple tumor antigens, modulating the inflammatory response, and inhibition of inflammatory dedifferentiation-inducing signals. Cancer Discov; 8(8); 935-43. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 899.
引用
- Mehta A, Kim YJ, Robert L, et al. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discov. 2018. PMID: 29899062. doi:10.1158/2159-8290.CD-17-1178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。